MacroGenics (MGNX)
(Real Time Quote from BATS)
$3.00 USD
-0.06 (-1.96%)
Updated Sep 24, 2024 11:18 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 1 - 20 ( 364 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Milestone Achieved; TAMARACK Trial Culled; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Vobra Duo Safety Profile Disappoints; 1Q24 Financials; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Early TAMARACK Safety Results; AACR Preclinical Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
TAMARACK Results Expected at ASCO; 2023 Financials; Modulating PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Investor Focus on Phase 2 Vobra Duo Data; Modulating PT to $14 and Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for MGNX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Receives FDA Accelerated Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
TZIELD Royalty Interest Monetized; 2022 Financials; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Teplizumab FDA Approval Triggers $60M Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Collaboration Agreement Inked With Gilead; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Competitive Landscape Updates From ESMO; Modulating PT Down to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Corporate Restructuring Announced; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Enoblituzumab Phase 2 Trial Culled on Safety Concerns; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Phase 2/3 Trial For MGC018 Slated For Year-End; 1Q22 Financials; Modulating PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Synaffix Agreement Provides Disruptive ADC Technologies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R